Compare SPCE & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCE | FENC |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.1M | 470.6M |
| IPO Year | 2017 | 2010 |
| Metric | SPCE | FENC |
|---|---|---|
| Price | $1.01 | $12.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $3.01 | ★ $17.60 |
| AVG Volume (30 Days) | ★ 9.1M | 255.2K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.84 | N/A |
| EPS | N/A | ★ 0.19 |
| Revenue | $1,544,000.00 | ★ $44,642,000.00 |
| Revenue This Year | N/A | $67.04 |
| Revenue Next Year | $18,784.17 | $44.54 |
| P/E Ratio | ★ N/A | $70.79 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.11 | $5.65 |
| 52 Week High | $8.90 | $13.85 |
| Indicator | SPCE | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 21.44 | 62.70 |
| Support Level | N/A | $9.58 |
| Resistance Level | $2.76 | $12.79 |
| Average True Range (ATR) | 0.23 | 0.92 |
| MACD | -0.17 | 0.31 |
| Stochastic Oscillator | 1.03 | 77.10 |
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.